ALS

This study looked at the long-term safety of an oral form of edaravone in 185 adults with ALS. Participants took the medication for 24 to 48 weeks, and researchers tracked any side effects. The goal was to see if taking the drug by mouth is safe over time for people with this pro…

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the med…

This phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months.…

This phase IIb trial tested PrimeC, a combination of two common drugs (ciprofloxacin and celecoxib), in 69 people with ALS. Participants took PrimeC or a placebo for 6 months, followed by a 12-month open-label extension where everyone received PrimeC. The study measured safety, s…

This study looked at whether a moderate-intensity breathing exercise program is safe and doable for people with ALS. Nine adults with ALS did four 3-week cycles of respiratory muscle training at home, with weekly check-ins via video call. The main goal was to see if participants …

This study follows about 74 adults with ALS who have already decided to take the drug Edaravone (Radicava). Researchers collect blood and urine samples over 24 weeks to measure various biomarkers—molecules that might show how the drug affects oxidative stress, inflammation, and n…

This study tests whether wearable sensors and digital home tasks can track changes in movement, speech, and falls in people with ALS. About 20 participants will wear neck and wrist sensors and complete speech and handwriting tests over 48 weeks. The goal is to see if these digita…

This study looked at how nerves in the spine work in people recently diagnosed with ALS compared to healthy volunteers. The goal was to find specific electrical signals that could help doctors understand the disease better and track its progress. 101 participants took part in tes…